Automotive Anti-Pinch Power Window System Market to Reach $3,611.2 Million by 2023     |    Orthodontic Supplies Market to Reach $5.9 Billion by 2023     |    Automotive HMI Market to Reach $39,695 Million by 2023
P&S Market Research - A market research firm

IgA Nephropathy Pipeline Analysis

P&S Market Research-IgA Nephropathy Pipeline Analysis report

IgA Nephropathy Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: April 2017
Report Code: LS10912
Available Format: pdf
Pages: 81

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Pipeline Overview

Immunoglobulin A Nephropathy, also known as IgA nephropathy (IgAN) or Berger’s disease, is a kidney disorder that arises when IgA builds up in the kidneys, resulting in inflammation which causes damage to kidney tissues. IgA is an immunoglobulin A antibody produced by immune system for body protection from foreign substances such as viruses or bacteria. Production of IgA deposits damages the glomeruli and this results in blood and protein in urine. This progresses over time and eventually results in end stage renal disease (ESRD).

IgA nephropathy is a silent disease in its early stages with no symptoms. But the most common symptoms that are usually observed are proteinuria, leakage of protein in urine and hematuria, leakage of blood in urine. These symptoms can be observed by naked eyes as the urine color changes in both the conditions. The other signs and symptoms include high blood pressure, dry skin, feeling tired, nausea, little urination, weight loss, appetite loss and sleeping problems.

IgA nephropathy does not have a specific treatment, since when the kidneys get damaged they cannot be repaired. So the only treatment available is to prevent or delay ESRD. The process of kidney damage can be slowed down by the use of fish oil supplements, immunosuppressive drugs, corticosteroids angiotensin receptor blockers (ARBs) and angiotensin-converting-enzyme (ACE) inhibitors.

Pipeline Analysis

As of March 2017, the IgA nephropathy pipeline comprises of approximately 12 drug candidates in different stages of development.

 

NUMBER OF IGA NEPHROPATHY DRUG CANDIDATES UNDER DEVELOPMENT (2017)

IgA Nephropathy Pipeline Analysis

 

Competitive Landscape

Some of the key players developing drugs for IgA nephropathy include Mallinckrodt plc, Merck KGaA, Anthera Pharmaceuticals, Inc. and others.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the last stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

1850
Group License

Group License authorizes access of the publication upto 5 users.

2500
Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.

5000
down-arrow

Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment